Morgan Stanley Cuts IQVIA Price Target to $240 After Q4 Beat
Morgan Stanley cut its price target on IQVIA to $240 from $265 while holding an Overweight rating. IQVIA reported Q4 revenue of $4.36B versus a $4.08B consensus and launched a collaboration with Duke Clinical Research Institute on obesity cardiometabolic trials.
1. Price Target Revision
On February 11, Morgan Stanley reduced its 12-month price target for IQVIA to $240 from $265, citing updated earnings estimates following the company’s quarterly report, while maintaining an Overweight rating on the shares.
2. Q4 Financial Results
IQVIA closed 2025 with fourth-quarter revenue of $4.36 billion, outpacing the $4.08 billion consensus, driven by near double-digit revenue and EPS growth across commercial and clinical segments, with R&DS net bookings hitting a yearly high and AI investments bolstering topline performance.
3. Duke Clinical Collaboration
On February 10, IQVIA and Duke Clinical Research Institute unveiled a strategic partnership focused on obesity and cardiometabolic clinical trials, aiming to accelerate trial planning and delivery through combined life science services and academic expertise.